Linzagolix

Linzagolix (KLH-2109; OBE-2109) is a potent, non-peptide, and orally active GnRH antagonist. Linzagolix can be used for uterine fibroids, endometriosis, adenomyosis research[1][2][3].

Product Specifications

CAS Number

[935283-04-8]

Product Name Alternative

KLH-2109; OBE-2109

UNSPSC

12352005

Target

GnRH Receptor

Type

Reference compound

Related Pathways

GPCR/G Protein

Applications

COVID-19-immunoregulation

Field of Research

Cancer; Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/linzagolix.html

Purity

99.68

Solubility

DMSO : 125 mg/mL (ultrasonic)

Smiles

O=C(C(SC=C1NC(N2C3=C(F)C=C(OC)C(OCC4=C(C(F)=CC=C4OC)F)=C3)=O)=C1C2=O)O

Molecular Formula

C22H15F3N2O7S

Molecular Weight

508.42

References & Citations

[1]Susan Dababou, et al. Linzagolix: a new GnRH-antagonist under investigation for the treatment of endometriosis and uterine myomas. Expert Opin Investig Drugs. 2021 Sep;30 (9) :903-911. |[2]Motohiro Tezuka, et al. Suppressive effects of linzagolix, a novel non-peptide antagonist of gonadotropin-releasing hormone receptors, in experimental endometriosis model rats. Clin Exp Pharmacol Physiol. 2023 Jul;50 (7) :610-617.|[3]Motohiro Tezuka, et al. Suppression of hypothalamic-pituitary-gonadal function by linzagolix in benign prostatic hyperplasia and polycystic ovary syndrome animal models. Clin Exp Pharmacol Physiol. 2023 Nov;50 (11) :914-923.